ABIO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases...

Stats
Today's Volume	73 568.00
Average Volume	1.45M
Market Cap	53.68M
EPS	$0 ( 2024-04-24 )
Next earnings date	( $0 ) 2024-07-19
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.81
ATR14	$0.0220 (0.59%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-30	Ma-weaver Jacob	Buy	6 000	Stock option (right to buy)
2024-01-30	Hove Anders D	Buy	6 000	Stock Option (right to buy)
2024-01-30	Mitchell Daniel J	Buy	6 000	Stock Option (right to buy)
2024-01-30	Flynn James P	Buy	6 000	Stock Option (right to buy)
2024-01-30	Conway Robert E	Buy	6 000	Stock Option (right to buy)

INSIDER POWER
98.28
Last 95 transactions
Buy: 2 938 848 \| Sell: 17 694 644

Volume Correlation

Long: 0.18 (neutral)

Short: 0.16 (neutral)

Signal:(61.345) Neutral

ARCA Biopharma Inc Correlation

10 Most Positive Correlations
OZEM	1
LABP	0.967
CENX	0.958
MESO	0.946
NN	0.946
CURI	0.945
STOK	0.941
VFF	0.94
PAYS	0.939
QRHC	0.937

10 Most Negative Correlations
EZGO	-0.956
QH	-0.955
LULU	-0.95
MBIO	-0.932
ALLR	-0.931
ATNF	-0.926
ATRC	-0.925
VEEE	-0.923
APVO	-0.922
POAI	-0.921

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ARCA Biopharma Inc Correlation - Currency/Commodity

-0.03
( neutral )

-0.33
( neutral )

0.00
( neutral )

0.06
( neutral )

-0.81
( strong negative )

ARCA Biopharma Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-111 000 (0.00 %)
EPS:	$-0.370

FY	2023
Revenue:	$0
Gross Profit:	$-111 000 (0.00 %)
EPS:	$-0.370

FY	2022
Revenue:	$0
Gross Profit:	$-114 000 (0.00 %)
EPS:	$-0.640

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.390

Financial Reports:

No articles found.

ARCA Biopharma Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

ARCA Biopharma Inc

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.